The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs

Journal of Psychiatry and Neuroscience

Volumn 31, Issue 3, 2006, Pages 168-176

  Chouinard, Guy ^a,b,c,d  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Allan Memorial Institute   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLONAZEPAM; CLOZAPINE; DULOXETINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LEVODOPA; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NICOTINAMIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; ZIMELDINE;

AGITATION; ANTICHOLINERGIC EFFECT; ANTICIPATORY ANXIETY; ANXIETY DISORDER; ARTHRALGIA; ATTENTION DEFICIT DISORDER; AUTONOMIC DYSFUNCTION; CHILL; CLINICAL TRIAL; DEPRESSION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG RECEPTOR BINDING; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GILLES DE LA TOURETTE SYNDROME; GUILLAIN BARRE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERSENSITIVITY REACTION; HYPOKINESIA; HYPOMANIA; INSOMNIA; MAJOR DEPRESSION; MANIA; MOOD DISORDER; MYALGIA; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PANIC; PRESCRIPTION; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; TREMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; HUMANS; MENTAL DISORDERS;

EID: 33745432015     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Chouinard G. Interrelations between psychiatric symptoms and drug-induced movement disorder. J Psychiatry Neurosci 2006;31(3):177-80.
2. Young SN, Sourkes TL. Antidepressant action of tryptophan. Lancet 1974;2(7885):897-8.
3. Chouinard G, Young SN, Annable L, et al. Tryptophan-nicotinamide in depression [letter]. Lancet 1977;1:249.
4. Chouinard G, Annable L, Fontaine R, et al. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) 1982;77:229-33.
5. Chouinard G, Annable L, Fontaine R, et al. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacol Bull 1983;19:115-6.
6. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983;18:451-66.
7. Chouinard G, Labonte A, Fontaine R, Annable L. New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1983;7(4-6):669-73.
8. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66:211-7.
9. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980;137:782-90.
10. Emrich HM, von Zerssen D, Kissling W, et al. Therapeutic effect of valproate in mania. Am J Psychiatry 1981;138:256.
11. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985;46:32-7.
12. Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive compulsive disorder. J Clin Psychopharmacol 1986;6:98-101.
13. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(Suppl B):18-27.
14. Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26:279-84.
15. Chouinard G, Annable L. Clozapine in the treatment of newly admitted schizophrenic patients. A pilot study. J Clin Pharmacol 1976;16:289-97.
16. Chouinard G, Jones BD, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
17. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962;119:432-8.
18. Spitzer RL, Andreasen N, Arnstein RL, et al, editors. Diagnostic and statistical manual of mental disorders (DSM-II). 2nd ed. Washington: American Psychiatric Association; 1968.
19. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria. 3rd ed. New York: Biometrics Research, New York State Psychiatric Institute; 1977.
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
21. Guy W, editor. ECDEU assessment manual for psychopharmacology (revised). Rockville (MD): National Institute of Mental Health Psychopharmacology Research Branch; 1976.
22. Sheehan DV. Current views on the treatment of panic and phobia disorders. Drug Ther Hosp 1982;7:74-93.
23. Liebowitz MR, Fyer AJ, Gorman JM, et al. Alprazolam in the treatment of panic disorders. J Clin Psychopharmacol 1986;6:13-20.
24. Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: 1. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-22.
25. Browne TR. Clonazepam. N Engl J Med 1978;299:812-6.
26. Chadwick D, Hallett M, Harris R, et al. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977;100:455-87.
27. Lorr ME, Klett CJ. Inpatient multidimensional psychiatric scale. Palo Alta (CA): Consulting Psychologists' Press; 1966.
28. Chouinard G. Antimanic effects of clonazepam. Psychosomatics 1985;26(Suppl 12):7-12.
29. Modell JG, Lenox RH, Weiner S. Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol 1985;5:109-13.
30. Lenox RH, Modell JG, Weiner S. Acute treatment of manic agitation with lorazepam. Psychosomatics 1986;27(Suppl 1):28-32.
31. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598-601.
32. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991;52:177-80.
33. Chouinard G, Annable L, Turnier L, et al. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and LM. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993;38 Suppl 4:S114-21.
34. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40.
35. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997;12:175-9.
36. Bieniek SA, Ownby RL, Penalver A, et al. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998;18:57-62.
37. McAllister-Williams RH, Ferrier IN. Rapid tranquilisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002;180:485-9.
38. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;20:339-46.
39. Fontaine R, Chouinard G. Antipanic effect of clonazepam [letter]. Am J Psychiatry 1984;141:149.
40. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.
41. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997;17:390-400.
42. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999;60:604-12.
43. Spitzer RL, Andreasen N, Arnstein RL, et al, editors. Diagnostic and statistical manual of mental disorders (DSM-III). 3rd ed. Washington: American Psychiatric Association; 1980.
44. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 1973;9:13-28.
45. Beaudry P, Fontaine R, Chouinard G, et al. Clonazepam in the treatment of patients with recurrent panic attacks. J Clin Psychiatry 1986;47:83-5.
46. Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111-8.
47. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65(Suppl 5):7-12.
48. Rosenbaum JF. The development of clonazepam as a psychotropic: the massachusetts general hospital experience. J Clin Psychiatry 2004;65(Suppl 5):3-6.
49. Chouinard G. Rebound anxiety: incidence and relationship to subjective cognitive impairment. J Clin Psychiatry Monograph 1986;4:12-6.
50. Fontaine R, Chouinard G, Annable L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984;141:848-52.
51. Chouinard G. Additional comments on benzodiazepine withdrawal. CMAJ 1988;139:119-20.
52. Chouinard G, Jones BD, Annable L. Neuroleptic-induced super-sensitivity psychosis. Am J Psychiatry 1978;135:1409-10.
53. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-21.
54. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991;5:21-33.
55. Chouinard G, Young SN, Annable L, et al. Tryptophan dosage critical for its antidepressant effect [letter]. BMJ 1978;1:1422.
56. Chouinard G, Young SN, Annable L, et al. Tryptophan-nicotinamide, imipramine and their combination in depression. Acta Psychiatr Scand 1979;59:395-414.
57. Chouinard G, Young SN, Bradwejn J, et al. Tryptophan in the treatment of depression and mania. In: van Praag HM, Mendlewicz J, editors. Advances in biological psychiatry. Vol. 10. Basel (Switzerland): Karger; 1983. p. 47-66.
58. Landry P, Chouinard G, Primneau F. Lithium-tryptophan combination in the maintenance treatment of bipolar affective illness. Lithium 1991;2:135-40.
59. Chouinard G. Tryptophan and its role in the step-care approach to the treatment of affective disorders. Can Rev Affect Disord 1991;1:1.
60. Chouinard G, Young SN, Annable L. A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry 1985;20:546-57.
61. Centers for Disease Control. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan - United States, through August 24, 1990. JAMA 1990;264:1655.
62. Kamb ML, Murphy JJ, Jones JL, et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992;267:77-82.
63. Chouinard G, Annable L, Bradwejn J. An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. [Berl], Psychopharmacology (Berl) 1984;83:126-8.
64. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
65. Chouinard G, Annable L, Bradwejn J, et al. An early phase II clinical trial with follow-up of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull 1985;21:73-6.
66. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693-5.
67. Beauclair L, Radoi-Andraous D, Chouinard G. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs). In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's comprehensive textbook of psychiatry. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 2427-32.
68. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18.
69. Chouinard G. Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry 1983;44:121-9.
70. Chouinard G, Annable L, Langlois R. Absence of orthostatic hypotension in depressed patients treated with bupropion. Prog Neuropsychopharmacol 1981;5:483-90.
71. FDA guidelines for the clinical evaluation of psychotropic drugs-antidepressant and antianxiety drugs. Psychopharm Bull 1978;14(2):45-63.
72. Bupropion (Zyban) for smoking cessation. Med Lett Drugs Ther 1997;39:77-8.
73. Landry P, Chouinard G. Obsessive-compulsive disorder: pathogenesis and fluoxetine treatment. Rev Contemp Pharmacother 1990;1:61-74.
74. Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 1980;136:1-25.
75. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-complusive disorder: a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-5.
76. Ananth J, Pecknold JC, Van Den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 1981;5:257-62.
77. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-12.
78. Kahn RS, Westenberg HG, Jolles J. Zimeldine treatment of obsessive-compulsive disorder. Biological and neuropsychological aspects. Acta Psychiatr Scand 1984;69:259-61.
79. Fontaine R, Chouinard G, Iny L. An open clinical trial of zimeldine in the treatment of obsessive compulsive disorder. Curr Ther Res 1985;37:326-32.
80. Asberg M, Montgomery SA, Perris C, et al. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl 1978;(271):5-27.
81. Nilsson BS. Adverse reactions in connection with zimeldine treatment: a review. Acta Psychiatr Scand Suppl 1983;308:115-9.
82. Nilsson BS, Lundberg G, Pottage A. Report of neuropathy in patients treated with zimeldine. Sodertalje (Sweden): Astra; 1983. Astra report no 805-04 AC071-1.
83. Chouinard G, Jones B. No cross-over of hypersensitivity reactions between zimelidine and fluoxetine [letter]. CMAJ 1984;131:1190.
84. Chouinard G, Fontaine R, Beaudry P, et al. The long-term use of fluoxetine in the treatment of depression and obsessive-compulsive disorder [lecture]. International Conference on New Directions in Affective Disorders; 1987 April 5-9; Jerusalem, Israel.
85. Fontaine R, Chouinard G. Anti-obsessive compulsive effect of fluoxetine [letter]. Am J Psychiatry 1985;142:989.
86. Fontaine R, Chouinard G. Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:605-8.
87. Fontaine R, Chouinard G. Fluoxetine in the long-term treatment of obsessive compulsive disorder. Psychiatr Ann 1989;19:88-91.
88. Laporta M, Chouinard G, Goldbloom D, et al. Hypomania induced by sertraline, a new serotonin reuptake inhibitor [letter]. Am J Psychiatry 1987;144:1513-4.
89. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:1012-6.
90. Murphy DL, Pickar D, Laterman IS. Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EI, Sudilovsky A, Gershon S, editors. The behavior of psychiatric patients. New York: Marcel Dekker; 1982. p. 355-92.
91. Hodgson RJ, Rachman S. Obsessional-compulsive complaints. Behav Res Ther 1977;15:389-95.
92. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992;7(Suppl 2):37-41.
93. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
94. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995;34:1147-52.
95. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996;57:29-31.
96. Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of tourette syndrome: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002;22:31-9.
97. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd ed. revised. Washington: the Association; 1987.
98. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-65.
99. Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001;62:50-6.
100. Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002;41:330-6.
101. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60:1130-5.
102. Chouinard G, Beauclair L, Bélanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders [letter]. Can J Psychiatry 1998;43:305.
103. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol [letter]. Am J Psychiatry 1995;152:1399.
104. Stanton SP, Keck PE, McElroy SL. Treatment of acute mania with gabapentin [letter]. Am J Psychiatry 1997;154:287.
105. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder [letter]. Am J Psychiatry 1997;154:291-2.
106. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
107. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin:a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
108. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington: the Association; 1994.
109. Rice AS, Maton S; Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
110. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
111. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28.
112. Pregabalin (Lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther 2005;47:75-7.